Verrica Pharmaceuticals Inc (NASDAQ:VRCA) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 573,300 shares, a decrease of 10.7% from the December 15th total of 641,900 shares. Approximately 4.7% of the company’s shares are short sold. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is currently 7.7 days.
NASDAQ VRCA traded up $0.27 during trading hours on Thursday, hitting $15.77. 1,848 shares of the company traded hands, compared to its average volume of 61,593. The business’s 50-day moving average is $15.00 and its 200-day moving average is $13.08. Verrica Pharmaceuticals has a twelve month low of $6.84 and a twelve month high of $18.67. The stock has a market capitalization of $403.38 million, a price-to-earnings ratio of -11.21 and a beta of 4.10.
Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03. As a group, research analysts forecast that Verrica Pharmaceuticals will post -1.13 EPS for the current fiscal year.
A number of research firms have issued reports on VRCA. Zacks Investment Research cut Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Verrica Pharmaceuticals in a research note on Wednesday, November 27th.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.